Fundraising Fox

VC23 Investors

Venture capital

Avon · Seed–Series A · 6 people tracked

Fox Verdict
Sign up to see your fit

Investment thesis

VC23 invests across sectors but concentrates on BioTools, arguing these companies scale faster and more capital-efficiently than therapeutics, reach revenue and partnerships earlier, and require less capital before exit while attracting steady acquisition interest from incumbents. The firm believes the convergence of compute, AI, and biology creates a multiplicative innovation feedback loop enabling faster drug discovery, scalable synthetic biology, and precision diagnostics. It applies deep technical and commercial diligence and uses AI-enhanced tools to uncover value others might miss, supported by Venture Partners who invest alongside the firm and provide operational expertise to portfolio companies.

Source: firm website, verified Aug 3, 2026.

Stage
Seed–Series A
HQ
Avon, Connecticut, US
Instruments
Equity
Founded
2018

Team · 6 people

from public directories
Nat Brinn· General Partnerin
Ron Evans· General Partner
Alan Mendelson· Venture Partner
Ralph Vossmeyer· Venture Partnerin
Tim Sullivan· Venture Partner

Frequently asked questions

What stage does VC23 Investors invest at?
VC23 Investors invests at the Seed, Series A stages.
What sectors does VC23 Investors focus on?
VC23 Investors focuses on AI & Machine Learning, Biotech, Healthtech, Medical Devices.
Where is VC23 Investors located?
VC23 Investors is headquartered in Avon, US.

Images

VC23 Investors photo

Similar investors

Featured in lists